Relapsed and Refractory Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting relapsed and refractory clinical trials across 3 countries. Studies span Phase 2, Early Phase 1, Not Applicable. Top locations include Coral Gables, Florida, United States, Deerfield Beach, Florida, United States, Fuzhou, Fujian, China. Updated daily from ClinicalTrials.gov.


Relapsed and Refractory Trials at a Glance

7 actively recruiting trials for relapsed and refractory are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Coral Gables, Deerfield Beach, and Fuzhou. Lead sponsors running relapsed and refractory studies include Institute of Hematology & Blood Diseases Hospital, China, Peter MacCallum Cancer Centre, and He Huang.

Browse relapsed and refractory trials by phase

Treatments under study

About Relapsed and Refractory Clinical Trials

Looking for clinical trials for Relapsed and Refractory? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Relapsed and Refractory trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Relapsed and Refractory clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Follicular LymphomaRelapsed and Refractory Follicular Lymphoma
Sun Yat-sen University32 enrolled3 locationsNCT04989621
Recruiting
Phase 2

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma
University of Miami33 enrolled3 locationsNCT05530421
Recruiting

Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell LymphomaTransarterial ChemoembolizationRelapsed and Refractory
Ting YANG10 enrolled1 locationNCT07198230
Recruiting
Not Applicable

CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

Relapsed and Refractory CD5 Hematological Tumors
Institute of Hematology & Blood Diseases Hospital, China18 enrolled1 locationNCT07234110
Recruiting
Phase 2

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Diffuse Large B Cell LymphomaRelapsed and Refractory
The First Affiliated Hospital of Xiamen University22 enrolled1 locationNCT06651853
Recruiting
Early Phase 1

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Lymphoid Hematological MalignanciesRelapsed and Refractory
He Huang100 enrolled1 locationNCT04283006
Recruiting
Phase 2

A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell Lymphoma

Relapsed and Refractory Indolent B-cell Lymphoma
Peter MacCallum Cancer Centre30 enrolled1 locationACTRN12612000746831